Workload implications and cost of statin treatment in the National Service Framework for Coronary Heart Disease

British Journal of Cardiology

Volumn 7, Issue SUPPL. 4, 2000, Pages

  Yeo, W W ^a   Yeo, K R ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DRUG MECHANISM; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NATIONAL HEALTH SERVICE; OUTCOMES RESEARCH; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WORKLOAD;

EID: 0033663739     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
3. Joint British recommendations on prevention of coronary heart disease in clinical practice
4. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
5. Modern standards and service models
6. Lipid-lowering for prevention of coronary heart disease: What policy now?
7. Sheffield risk and treatment table for cholesterol-lowering for primary prevention of coronary heart disease
8. Cardiovascular disease risk profiles
9. Is the Framingham risk function valid for Northern European populations? A comparison of methods for estimating absolute coronary risk in high-risk men
10. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
11. Comparative dose efficacy study of atorvastatin versusu simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolaemia (the CURVES study)
12. Efficacy and six-month safety of simvastatin 80 mg/day: Results from the Worldwide Simvastatin Expanded Dose Program (WSEDP)
13. Maximizing the cost-effectiveness of lipid-lowering therapy
14. North of England evidence based guideline development project: Guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care
15. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
16. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): Lipid and metabolic factors related to atheroma and clinical events
17. A randomised placebo controlled trial of fluvastatin for the prevention of restenosis after successful coronary balloon angioplasty: Final results of the fluvastatin angiographic restenosis (FLARE) trial
18. The effects of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
19. Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease